Open-heart surgery in patients that have suffered major cardiovascular events is risky, but it could be getting less so thanks to temporary heart pumps sold by Abiomed (NASDAQ: ABMD), a $17 billion market-cap medical devices company. Is Abiomed a stock worth including in your portfolio?
Abiomed's Shares Doubled. What Happens Next?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться